Cabaletta Bio, Inc.
CABA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001759138
No open-market purchases or sales by Cabaletta Bio, Inc. insiders were filed in the last 90 days; 139 institutions reported holding it in 13F filings for Q2 2026, worth $490.4M in total; no superinvestor holds it.
13F holders, Q1 2026
Institutional positions in Cabaletta Bio, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 108
- +14 vs. Q4 2025
- Shares held
- 84.7M
- +12.8M (+17.9%) vs. Q4 2025
- Total value
- $227.5M
- +$70.3M (+44.7%) vs. Q4 2025
- New holders
- 27
- 32 more added
- Sold out
- 13
- 27 more reduced
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CABA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 139 | $490.4M |
| Q1 2026 | 108 | $227.5M |
| Q4 2025 | 95 | $166.9M |
| Q3 2025 | 75 | $162.0M |
| Q2 2025 | 86 | $110.7M |
| Q1 2025 | 93 | $50.3M |
| Q4 2024 | 109 | $87.2M |
| Q3 2024 | 120 | $226.7M |
| Q2 2024 | 142 | $380.0M |
| Q1 2024 | 159 | $870.9M |
| Q4 2023 | 128 | $1.10B |
| Q3 2023 | 97 | $622.6M |
| Q2 2023 | 84 | $470.5M |
| Q1 2023 | 72 | $203.9M |
| Q4 2022 | 61 | $183.9M |
| Q3 2022 | 54 | $7.76M |
| Q2 2022 | 55 | $17.8M |
| Q1 2022 | 62 | $36.9M |
| Q4 2021 | 66 | $68.9M |
| Q3 2021 | 61 | $211.3M |
| Q2 2021 | 63 | $135.5M |
| Q1 2021 | 68 | $180.1M |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Cabaletta Bio, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Two Sigma Investments, LP | 2,497,917 | $6.72M | 0.01% | +658,118+35.8% | Added |
| Vanguard Capital Management LLC | 4,028,991 | $10.8M | 0.00% | +4,028,991 | New |
| Cormorant Asset Management, LP | 5,500,000 | $14.8M | 0.75% | +1,100,000+25.0% | Added |
| Millennium Management LLC | 5,903,281 | $15.9M | 0.01% | +3,166,369+115.7% | Added |
| Adage Capital Partners GP, L.L.C. | 8,829,758 | $23.8M | 0.04% | 00.0% | Unchanged |
| Jennison Associates LLC | 8,970,578 | $24.1M | 0.02% | +64,879+0.7% | Added |
| Bain Capital Life Sciences Investors, LLC | 9,677,125 | $26.0M | 2.35% | 00.0% | Unchanged |
| T. Rowe Price Investment Management, Inc. | 11,080,005 | $29.8M | 0.02% | +1,221,748+12.4% | Added |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −737,900−100.0% | Sold out |
| Ensign Peak Advisors, Inc | 0 | $0 | 0.00% | −550,000−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −138,281−100.0% | Sold out |
| Lighthouse Investment Partners, LLC | 0 | $0 | 0.00% | −38,880−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −33,502−100.0% | Sold out |
| SG Americas Securities, LLC | 0 | $0 | 0.00% | −30,629−100.0% | Sold out |
| Manufacturers Life Insurance Company, The | 0 | $0 | 0.00% | −13,011−100.0% | Sold out |
| HB Wealth Management, LLC | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Canada Pension Plan Investment Board | 0 | $0 | 0.00% | −3,500−100.0% | Sold out |
| Flagship Harbor Advisors, LLC | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| Truvestments Capital LLC | 0 | $0 | 0.00% | −680−100.0% | Sold out |
| Optiver Holding B.V. | 0 | $0 | 0.00% | −24−100.0% | Sold out |
| Covestor Ltd | 0 | $0 | 0.00% | −34−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |